For research use only. Not for therapeutic Use.
STL001 is a FOXM1 inhibitor and exhibits selectivity toward suppressing FOXM1-controlled regulatory pathways. STL001 preserves the mode of action of STL427944 (Axon 4050), but is up to 50 times more efficient in reducing FOXM1 activity in a variety of solid cancers. KEYWORDS: STL001 | Supplier | FOXM1 inhibitor | STL 001 | STL-001 | CAS [3047493-70-6] | DNA-RNA | FOXM1 | Inhibitor | Transcription Factors | Forkhead box protein M1
| Catalog Number | I047717 |
| CAS Number | 3047493-70-6 |
| Molecular Formula | C27H23N7O4 |
| Purity | ≥95% |
| IUPAC Name | 1-[5-(diethylamino)-2-[(Z)-(fluoren-9-ylidenehydrazinylidene)methyl]phenoxy]-3-[4-[3-[5-(diethylamino)-2-[(Z)-(fluoren-9-ylidenehydrazinylidene)methyl]phenoxy]-2-hydroxypropoxy]butoxy]propan-2-ol;1-[5-(diethylamino)-2-[(Z)-(fluoren-9-ylidenehydrazinylidene)methyl]phenoxy]-3-[3-[3-[5-(diethylamino)-2-[(Z)-(fluoren-9-ylidenehydrazinylidene)methyl]phenoxy]-2-hydroxypropoxy]phenoxy]propan-2-ol;1-[5-(diethylamino)-2-[(Z)-(fluoren-9-ylidenehydrazinylidene)methyl]phenoxy]-3-[2-[3-[5-(diethylamino)-2-[(Z)-(fluoren-9-ylidenehydrazinylidene)methyl]phenoxy]-2-hydroxypropyl]sulfanylethylsulfanyl]propan-2-ol;methane |
| InChI | InChI=1S/C60H60N6O6.C58H64N6O6.C56H60N6O4S2.3CH4/c1-5-65(6-2)43-30-28-41(35-61-63-59-53-24-13-9-20-49(53)50-21-10-14-25-54(50)59)57(32-43)71-39-45(67)37-69-47-18-17-19-48(34-47)70-38-46(68)40-72-58-33-44(66(7-3)8-4)31-29-42(58)36-62-64-60-55-26-15-11-22-51(55)52-23-12-16-27-56(52)60;1-5-63(6-2)43-29-27-41(35-59-61-57-51-23-13-9-19-47(51)48-20-10-14-24-52(48)57)55(33-43)69-39-45(65)37-67-31-17-18-32-68-38-46(66)40-70-56-34-44(64(7-3)8-4)30-28-42(56)36-60-62-58-53-25-15-11-21-49(53)50-22-12-16-26-54(50)58;1-5-61(6-2)41-27-25-39(33-57-59-55-49-21-13-9-17-45(49)46-18-10-14-22-50(46)55)53(31-41)65-35-43(63)37-67-29-30-68-38-44(64)36-66-54-32-42(62(7-3)8-4)28-26-40(54)34-58-60-56-51-23-15-11-19-47(51)48-20-12-16-24-52(48)56;;;/h9-36,45-46,67-68H,5-8,37-40H2,1-4H3;9-16,19-30,33-36,45-46,65-66H,5-8,17-18,31-32,37-40H2,1-4H3;9-28,31-34,43-44,63-64H,5-8,29-30,35-38H2,1-4H3;3*1H4/b61-35-,62-36-;59-35-,60-36-;57-33-,58-34-;;; |
| SMILES | C.C.C.CCN(C1=CC(=C(C=C1)/C=N\N=C2C3=CC=CC=C3C4=CC=CC=C24)OCC(O)COCCCCOCC(O)COC5=C(C=CC(=C5)N(CC)CC)/C=N\N=C6C7=CC=CC=C7C8=CC=CC=C68)CC.CCN(C1=CC(=C(C=C1)/C=N\N=C2C3=CC=CC=C3C4=CC=CC=C24)OCC(O)COC5=CC(=CC=C5)OCC(O)COC6=C(C=CC(=C6)N(CC)CC)/C=N\N=C7C8=CC=CC=C8C9=CC=CC=C79)CC.CCN(C1=CC(=C(C=C1)/C=N\N=C2C3=CC=CC=C3C4=CC=CC=C24)OCC(O)CSCCSCC(O)COC5=C(C=CC(=C5)N(CC)CC)/C=N\N=C6C7=CC=CC=C7C8=CC=CC=C68)CC |
| Reference | S Raghuwanshi et al. Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies. Cell Death Discov. 2024 May 2;10(1):211. |
